

CITATION REPORT

List of articles citing

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas

DOI: 10.1200/jco.2005.01.8267

Journal of Clinical Oncology, 2006, 24, 379-85.

Source: <https://exaly.com/paper-pdf/39985930/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
64	Second-Line Treatment of Non-small Cell Lung Cancer: Big Targets, Small Progress; Small Targets, Big Progress?. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 927-928	8.9	3
63	Second-Line Treatment of Non-small Cell Lung Cancer: Big Targets, Small Progress; Small Targets, Big Progress?. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 927-928	8.9	6
62	Current therapies and advances in the treatment of pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 58, 231-41	7	76
61	Toxicities of antiangiogenic therapy in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2006 , 8 Suppl 1, S23-30	4.9	41
60	Gemcitabine doublets in advanced pancreatic cancer: should we move on?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 327-9	2.2	11
59	Role of bevacizumab for the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2007 , 3, 131-9	3.6	11
58	Recent advances in targeted therapy for non-small cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 245-57	6.4	24
57	Role of radiation therapy in localized aggressive lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 757-9	2.2	17
56	Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 299-306	12.9	17
55	Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. <i>Cancer Research</i> , 2007 , 67, 10078-86	10.1	26
54	Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007 , 37, 515-20	2.8	9
53	Complete remission of a metastatic pancreatic carcinoma after modified G-FLIP therapy. <i>Chemotherapy</i> , 2007 , 53, 356-9	3.2	2
52	Targeted therapies and non-small-cell lung cancer: new developments. <i>Current Opinion in Oncology</i> , 2007 , 19, 75-7	4.2	3
51	Current World Literature. <i>Current Opinion in Organ Transplantation</i> , 2007 , 12, 89-118	2.5	
50	FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 15-20	2.7	47
49	Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2007 , 18, 263-71	2.4	15
48	Place actuelle des anti-angiogéniques dans le traitement des cancers bronchiques primitifs. <i>Revue Des Maladies Respiratoires</i> , 2007 , 24, 198-205	0	0

47	Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. <i>Journal of Translational Medicine</i> , 2007 , 5, 60	8.5	90
46	Erlotinib in non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2579-92	4	10
45	Combination of target agents: challenges and opportunities. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S4-6	8.9	3
44	E03-02: Targeted therapy for non-small cell lung cancer: beyond EGFR and VEGF. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S220-S221	8.9	
43	A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 809-16	4	85
42	Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 60, 601-7	3.5	9
41	A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?. <i>Investigational New Drugs</i> , 2008 , 26, 463-71	4.3	65
40	Quality of life in pancreatic cancer: analysis by stage and treatment. <i>Journal of Gastrointestinal Surgery</i> , 2008 , 12, 783-93; discussion 793-4	3.3	79
39	Addressing the needs of young breast cancer survivors at the 5 year milestone: can a short-term, low intensity intervention produce change?. <i>Journal of Cancer Survivorship</i> , 2008 , 2, 190-204	5.1	66
38	Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. <i>Cancer Investigation</i> , 2008 , 26, 47-52 ^{2,1}		18
37	Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5401-6	2.2	180
36	New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. <i>Oncologist</i> , 2008 , 13, 289-98	5.7	73
35	How I treat pancreatic ductal adenocarcinoma. <i>Journal of Oncology Practice</i> , 2008 , 4, 46-7	3.1	
34	Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. <i>Journal of Chemotherapy</i> , 2008 , 20, 119-25	2.3	8
33	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. <i>Clinical Cancer Research</i> , 2008 , 14, 1455-63	12.9	265
32	Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2008 , 19, 340-7	10.3	60
31	Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?. <i>Acta Oncologica</i> , 2008 , 47, 110-9	3.2	20
30	Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. <i>Pancreas</i> , 2008 , 37, 269-74	2.6	70

29	Pancreas cancer survival in the gemcitabine era. <i>Clinical Medicine Oncology</i> , 2008 , 2, 405-13		2
28	Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. <i>Oncology</i> , 2009 , 76, 333-7	3.6	16
27	Understanding and managing the possible adverse effects associated with bevacizumab. <i>American Journal of Health-System Pharmacy</i> , 2009 , 66, 999-1013	2.2	76
26	Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy. <i>Internal Medicine</i> , 2009 , 48, 1651-6	1.1	1
25	Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). <i>Oncology Reports</i> , 2010 , 23, 1183-92	3.5	107
24	Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2598-603	2.2	101
23	Systemic therapy for metastatic pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 85-106	5.4	4
22	Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. <i>Radiology</i> , 2010 , 256, 441-9	20.5	85
21	Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 6071-82	12.9	41
20	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 519-25	3.5	9
19	Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 371-8	3.5	4
18	[Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities]. <i>Revue Des Maladies Respiratoires</i> , 2012 , 29, 161-77	0	1
17	Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 381-9	3.5	16
16	Considerations for the prediction of survival time in pancreatic cancer based on registry data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013 , 40, 527-36	2.7	2
15	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013 , 31, 685-95	4.3	22
14	A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013 , 36, 250-3	2.7	4
13	Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4127-33	2.2	64
12	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. <i>Cancer</i> , 2014 , 120, 1780-6	6.4	22

11	Hereditary Pancreatic Cancer Syndromes. <i>Surgical Oncology Clinics of North America</i> , 2015 , 24, 733-64	2.7	23
10	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. <i>Medical Oncology</i> , 2016 , 33, 4	3.7	1
9	Cytotoxic Chemotherapy. 2017 , 220-235		
8	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 75-82	5.4	34
7	Response to Drs Von Hoff and Renschler. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 445-446	5.4	
6	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018 , 142, 1671-1675	7.5	7
5	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1603-1610	2.2	63
4	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. <i>Pancreas</i> , 2019 , 48, 1274-1284	2.6	2
3	Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer. 2008 , 511-533		1
2	CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 898-902	2.7	8
1	Oncological Management of Pancreatic Cancer in Advanced Stages. 2008 , 549-557		